Head and Neck Cancer

REACH safety data: avelumab plus RT-cetuximab in LA SCCHN 1:21
REACH safety data: avelumab plus RT-cetuximab in LA SCCHN
Jean Bourhis • 27 Sep 2019
CRT and Debio1143 for treatment of LA SCCHN 1:01
CRT and Debio1143 for treatment of LA SCCHN
Jean Bourhis • 27 Sep 2019
Phase III trial: chemotherapy plus local-regional radiotherapy in pmNPCC 2:22
Phase III trial: chemotherapy plus local-regional radiotherapy in pmNPCC
Ming-Yuan Chen • 1 Oct 2019
NPC communication between the West and China 1:02
NPC communication between the West and China
Ming-Yuan Chen • 1 Oct 2019
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing 1:48
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe • 10 Oct 2019
Improving patient selection for surgical candidates with head and neck cancer 2:27
Improving patient selection for surgical candidates with head and neck cancer
Hisham Mehanna • 28 Sep 2019
Update on oncolytic viruses for cancer treatment 3:01
Update on oncolytic viruses for cancer treatment
Kevin Harrington • 27 Sep 2019
The value of PD-L1 as a biomarker beyond lung cancers 2:13
The value of PD-L1 as a biomarker beyond lung cancers
Kevin Harrington • 27 Sep 2019
TKIs for treating medullary thyroid cancer 2:59
TKIs for treating medullary thyroid cancer
Jolanta Krajewska
The omega score: an emerging biomarker for risk determination 2:12
The omega score: an emerging biomarker for risk determination
Hisham Mehanna
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT 1:23
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
Hisham Mehanna
Cemiplimab prospects: CRC, CSCC & HNSCC 1:43
Cemiplimab prospects: CRC, CSCC & HNSCC
Hani Babiker
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC 3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
Checkpoint inhibitors for head and neck cancer in the definitive setting? 0:58
Checkpoint inhibitors for head and neck cancer in the definitive setting?
Barbara Burtness
HiLo: low risk thyroid cancer can be treated with lower doses of radiation 3:21
HiLo: low risk thyroid cancer can be treated with lower doses of radiation
Jonathan Wadsley
Immunotherapeutic landscape for head and neck cancer 2:36
Immunotherapeutic landscape for head and neck cancer
Quynh-Thu Le
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals